Cell Coast 2025 Presentations
Friday, October 17
Bispecific Antibody Therapy in Non-Hodgkin Lymphoma and Toxicity Management
Bijal Shah, MD | Moffitt Cancer Center
Operationalization of Tarlatamab Therapy at Moffitt Cancer Center
Sonam Puri, MD | Moffitt Cancer Center
Bispecific Antibody Therapy for Relapsed/Refractory Multiple Myeloma
Kenneth Shain, MD, PhD | Moffitt Cancer Center
Saturday, October 18
SESSION 1 - NOVEL TARGETS AND APPROACHES: MODERATOR: CIARA FREEMAN, MD
Novel Cellular Therapies for Sarcoma
Sandra D’Angelo, MD | Memorial Sloan Kettering Cancer Center
CAR T Cell Updates in ALL
Bijal Shah, MD | Moffitt Cancer Center
GPC3 CAR T Cells for the Management of Advanced Cancers
David Steffin, MD | Baylor College of Medicine/Texas Children’s Hospital
CAR-T for Autoimmune Diseases
Sayeef Mirza, MD | Moffitt Cancer Center
Biomarkers for Toxicity and Response in CAR-T for Multiple Myeloma
Doris Hansen, MD | Moffitt Cancer Center
In-Vivo CAR-T
Laura Volta, MD | Penn Medicine
SESSION 2 - ADVANCED ENGINEERING AND MODALITIES: MODERATOR MICHAEL JAIN, MD
Claudin 18.2 for Gastrointestinal Malignancies
Dae Won Kim, MD | Moffitt Cancer Center
T Cell Fitness: What’s Next after BCMA CAR
Ciara Freeman, MD | Moffitt Cancer Center
Armored CAR-T Strategies for Advanced Cancers
Marco Davila, MD | Roswell Park
Allogeneic “off the shelf” IO approaches for MDS/AML
David Sallman, MD | Moffitt Cancer Center
CAR-NK Strategies for the Management of Advanced Cancers
May Daher, MD | MD Anderson Cancer Center
Bladder Til Trial
Michael Poch, MD | Moffitt Cancer Center
SESSION 3 - OPTIMIZING DELIVERY AND EFFICACY: MODERATOR: JOHN MULLINAX, MD
Future of TIL Therapy
David Olson, MD | University of Chicago
Novel TIL Therapies in Lung Cancer
Adam Schoenfeld, MD | Memorial Sloan Kettering Cancer Center
Combination CAR-T Strategies: CD19/CD22 CART and Orca-T allo-SCT in BALL
Lori Muffly, MD | Stanford Medicine
CAR-T for Glioblastoma
Brian Stocksdale, MD | Stanford Medicine
GCC19 CAR T Trial
Benjamin Schlechter, MD | Dana Farber Cancer Institute
SESSION 4 - DEBATE AND AN APRNS POINT OF VIEW: MODERATOR: FRED LOCKE, MD
Practical /Logistics of Clinical Care for Cell Therapy Patients
Marian Dam, APRN | Moffitt Cancer Center
Debate: CAR-T vs BITEs for Hematologic Malignancies
Michael Jain, MD | Moffitt Cancer Center vs.
Omar Castaneda-Puglianini, MD | Moffitt Cancer Center